The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.

The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.

The invention provides topical pharmaceutical gel compositions for the treatment of chronic skin damage, specifically for damage caused by neuropathic ulcers and preferably for the treatment of diabetic foot, and in the treatment of vascular ulcers wherein said compositions comprise a combination of Modified Diallyl Disulfide Oxide (M-DDO) (as an antiseptic/antibiotic agent) and 5-methyl-1-phenyl-2(1H)-pyridone. Furthermore, the invention describes methods of treatment, applications and/or pharmaceutical uses in the preparation of medicaments for eliminating, reducing or preventing chronic skin lesions and the damages caused by neuropathic ulcers and particularly in the treatment of diabetic foot and in the treatment of vascular ulcers.

The present invention relates to a pharmaceutical combination comprising: (a) a PPAR agonist; (b) a p38 kinase inhibitor; and optionally (c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of preventing or treating ophthalmic diseases or disorders in a subject.

The present invention relates to a pharmaceutical combination comprising: (a) a PPAR agonist; (b) a p38 kinase inhibitor; and optionally (c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of preventing or treating ophthalmic diseases or disorders in a subject.

Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like. ##STR00001##

The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like. ##STR00001##

Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.